Bristol Myers Squibb Prices €5 Billion Senior Unsecured Notes Offering
Bristol-Myers Squibb Company $(BMY)$ has priced a public offering of senior unsecured notes with a combined aggregate principal amount of €5 billion, to be issued by its wholly-owned subsidiary, BMS Ireland Capital Funding Designated Activity Company. The offering comprises five tranches: - €750,000,000 of 2.973% Notes due 2030 - €1,150,000,000 of 3.363% Notes due 2033 - €1,150,000,000 of 3.857% Notes due 2038 - €750,000,000 of 4.289% Notes due 2045 - €1,200,000,000 of 4.581% Notes due 2055 The Notes will be fully and unconditionally guaranteed on a senior unsecured basis by Bristol-Myers Squibb Company. Closing of the offering is expected on November 10, 2025, subject to customary conditions. The company plans to use the net proceeds, along with approximately $3.0 billion in cash on hand, primarily to fund a concurrent tender offer and for general corporate purposes. The full prospectus is available at https://www.sec.gov.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20251105576757) on November 05, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.